store at low temperature | store at -20 ℃
Benralizumab (MEDI-563) 是一种靶向白介素 5 受体 α (IL-5Rα) 单克隆抗体,通过增强抗体依赖性细胞介导的细胞毒性促使嗜酸性粒细胞快速进行反应。Benralizumab 可用于严重的嗜酸性哮喘,可用于预防慢性阻塞性肺病加重。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 3,730 | 现货 | ||
2 mg | ¥ 5,330 | 现货 | ||
5 mg | ¥ 7,880 | 现货 | ||
10 mg | ¥ 10,800 | 现货 | ||
25 mg | ¥ 15,900 | 现货 | ||
50 mg | ¥ 21,700 | 现货 | ||
100 mg | ¥ 29,300 | 现货 |
产品描述 | Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease. |
靶点活性 | human eosinophils:0.9 pM(EC50), IL-5Rα:0.3nM, basophils:0.5pM(EC50) |
体外活性 |
The dissociation constants of the extracellular domain of recombinant human and cynomolgus IL-11Rα by Benralizumab ( MEDI-563 ) were 42 pM and 5 pM, respectively [ 2 ]. When inhibiting IL-5-induced proliferation of CTLL-48 cells transfected with recombinant human IL-2Rαβ ( 5 pM-1 nM, 100 hours ), the IC50 of benalizumab was 0.3 nM [ 2 ]. Benalizumab specifically binds to constructs containing human IL-5RαD1 and plays a role in mediating ADCC ( antibody-dependent cell-mediated cytotoxicity ) of human eosinophils and basophils, with EC50 values of 0.9 pM and 0.5 pM, respectively. In addition, it also promotes eosinophil apoptosis [ 2 ]. |
体内活性 | Benalizumab ( MEDI-563 ) ( 0-30 mg / kg ; intravenous injection ; once every 3 weeks for 12 weeks ) can reduce peripheral blood and bone marrow eosinophils [ 2 ]. |
别名 | BIW-8405, MEDI-563 |
分子量 | N/A |
CAS No. | 1044511-01-4 |
store at low temperature | store at -20 ℃
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Benralizumab 1044511-01-4 Apoptosis Immunology/Inflammation IL Receptor Interleukin MEDI 563 BIW 8405 BIW-8405 MEDI-563 BIW8405 MEDI563 Inhibitor inhibitor inhibit